Pent-up private Wegovy demand prompts UK availability concerns

Access to Novo Nordisk's weight-loss drug Wegovy in the UK may be easier for those who can afford to pay out of pocket, potentially exacerbating health inequality in a country with high obesity rates and an overburdened state-run health service, according to doctors and medical experts.

reuters.com

Relevant topic timeline:

8/21/2023

How soaring demand for Ozempic and Wegovy is altering Denmark's economy

Sales of the weight-loss drug Wegovy, manufactured by Novo Nordisk, have led to lower interest rates in Denmark due to an influx of US dollars into the country's economy, which has pushed up the value of the Danish krone.

9/1/2023

Weight loss drugmaker Novo Nordisk vies to become Europe's most valuable company, toppling LVMH

Novo Nordisk briefly surpassed LVMH to become Europe's most valuable company on the back of its weight loss drugs, but LVMH regained the top spot, although Novo Nordisk remains close behind with its highly anticipated drugs.

9/5/2023

Ozempic and Wegovy maker ‘just scratching the surface’ in meeting demand for weight loss drugs, CEO says

The CEO of Novo Nordisk, Lars Fruergaard Jorgensen, stated that it may take several years to meet the demand for the weight loss drug Wegovy, as the company struggles to keep up with the needs of over 100 million Americans with obesity.

9/6/2023

Morning Bid: Shedding pounds, buying dollars

Investors are eagerly anticipating the release of Novo Nordisk's weight-loss injection in British stores, while Manchester United shares plummeted after reports of the club being taken off the market; meanwhile, the dollar is strengthening, oil prices are rising, and concerns about weak demand and China's economy persist.

9/20/2023

Ypsomed Signs Long-Term Deal to Supply Autoinjectors for Novo Nordisk's Diabetes and Obesity Drugs

Ypsomed has announced a long-term supply deal with Novo Nordisk for autoinjectors, indicating the success of Novo Nordisk's weight-loss drug business and the potential for growth in the obesity market.

9/20/2023

New Obesity Drugs Could Transform Health but Disrupt Major Industries

Anti-obesity drugs developed by Novo Nordisk and Eli Lilly have the potential to transform public health but could also disrupt industries such as food, fitness, and healthcare, affecting companies like Nestlé and McDonald's.

9/21/2023

New Obesity Drugs Promise Weight Loss But Could Overwhelm Health System

The introduction of weight-loss drugs like Wegovy could lead to a healthcare crisis, as the cost and demand for these medications may overwhelm insurers, employers, and government programs that purchase medications in the United States.

Topics

Posted 9/5/2023, 1:02:00 PM

Pent-up private Wegovy demand prompts UK availability concerns

reuters.com

Relevant topic timeline:

8/21/2023

How soaring demand for Ozempic and Wegovy is altering Denmark's economy

9/1/2023

Weight loss drugmaker Novo Nordisk vies to become Europe's most valuable company, toppling LVMH

9/5/2023

Ozempic and Wegovy maker ‘just scratching the surface’ in meeting demand for weight loss drugs, CEO says

9/6/2023

Morning Bid: Shedding pounds, buying dollars

9/20/2023

Ypsomed Signs Long-Term Deal to Supply Autoinjectors for Novo Nordisk's Diabetes and Obesity Drugs

9/20/2023

New Obesity Drugs Could Transform Health but Disrupt Major Industries

9/21/2023

New Obesity Drugs Promise Weight Loss But Could Overwhelm Health System